FDA Approval Alert: The Need-to-Know | Penpulimab in Non-Keratinizing Nasopharyngeal Carcinoma

In April 2025, the FDA approved penpulimab-kcqx with cisplatin or carboplatin and gemcitabine as a first-line treatment for adult patients with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.

Data from the phase 3 AK105-304 study support the approval of penpulimab in this nasopharyngeal carcinoma population.
FDA Approves Penpulimab in Non-Keratinizing Nasopharyngeal Carcinoma
Article
Apr 24, 2025 2:39 PM
Data from the phase 3 AK105-304 study support the approval of penpulimab in this nasopharyngeal carcinoma population.